HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Variations in clinical PET/CT operations: results of an international survey of active PET/CT users.

AbstractUNLABELLED:
This study gathered information about clinical PET/CT operations worldwide to help guide discussions on the use and standardization of clinical PET/CT.
METHODS:
A Web-based survey of PET/CT users was initiated in November 2009 through e-mail advertising using Academy of Molecular Imaging databases. Recipients were asked 58 questions related to demographics (e.g., location, number of PET/CT systems, and staffing), PET/CT operations and use, and variations in (18)F-FDG oncology imaging protocols.
RESULTS:
The responders were from centers in the Americas (71%), Europe (22%), Asia-Pacific (6%), and Middle East (1%), with most responding sites representing public health care institutions (60%). PET/CT systems were most frequently installed in nuclear medicine departments (59%). Of the sites operating a PET/CT system, 16% had 10 y or more of stand-alone PET experience. About 40% of all sites operated at least 2 PET/CT systems. PET/CT was most frequently used for applications in torso or whole-body oncology (87%), radiation therapy planning (4%), cardiology (4%), and neurology (5%). The average interval of fasting before an (18)F-FDG PET/CT examination was 7 ± 3 h (range, 4-12 h). Blood glucose levels were measured at 99% of sites, but acceptable maximal glucose levels varied substantially (an upper limit of 200 mg/dL was applied at >50% of the institutions). A weight-based radioactivity dose injection was performed at 44% of sites. The mean (18)F-FDG activity injected was 390 MBq (range, 110-585 MBq) for 3-dimensional PET of a 75-kg patient. The mean uptake time was 64 ± 14 min (range, 20-90 min). Split protocols involving patient repositioning and adapted imaging parameters were used at 51% of sites. Only 41% used patient positioning aids. Intravenous or oral CT contrast material was used at 52% of sites in up to 25% of patients. Most sites (90%) measured maximum standardized uptake value as an index of tissue glucose use. Only 62% of sites provided a fully integrated PET/CT report.
CONCLUSION:
An international survey among clinical PET/CT users revealed significant variations in standard (18)F-FDG PET/CT protocols. This finding illustrates the need for continuous training and ongoing standardization in an effort to optimize PET/CT in oncology.
AuthorsThomas Beyer, Johannes Czernin, Lutz S Freudenberg
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 52 Issue 2 Pg. 303-10 (Feb 2011) ISSN: 1535-5667 [Electronic] United States
PMID21233186 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Blood Glucose
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
Topics
  • Blood Glucose (metabolism)
  • Cyclotrons
  • Data Collection
  • Diet
  • Fluorodeoxyglucose F18 (standards)
  • Humans
  • Image Processing, Computer-Assisted (standards)
  • Positron-Emission Tomography (instrumentation, standards)
  • Radiopharmaceuticals (standards)
  • Reference Standards
  • Tomography, Emission-Computed (instrumentation, standards)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: